Literature DB >> 21940830

A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma.

Irina Bonzheim, Itziar Salaverria, Andrea Haake, Günther Gastl, Patrick Adam, Reiner Siebert, Falko Fend, Leticia Quintanilla-Martinez.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940830      PMCID: PMC3179408          DOI: 10.1182/blood-2011-07-368944

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
We appreciate the interest shown in our work. In their comment, Visentini et al used cell proliferation studies to conclude that VH1-69-positive CD21high B cells in HCV patients with mixed cryoglobulinemia are anergic. However, B-cell anergy was initially operationally defined as the inability to differentiate into antibody-producing cells on stimulation. By this definition, our data (Figure 7 in Charles et al) demonstrate that CD21low, VH1-69-positive B cells are anergic, as these cells fail to produce high levels of antibody after stimulation with CD40L, IL-2, and IL-10. In contrast, we find that the CD21high subset does produce antibody after stimulation in vitro. We speculate that this population may be a source of the excessive IgM rheumatoid factor that is typically seen in HCV patients with mixed cryoglobulinemia. Visentini et al also question whether our calcium mobilization assays were affected by contaminating VH1-69–negative CD21high B cells. Positive selection or gating of VH1-69–expressing B cells for these assays would entail the use of the anti-idiotype antibody, G6, which could stimulate the B-cell antigen receptor (BCR) and impact subsequent analyses. Rather, we used negative selection and gating methods to avoid stimulating the VH1-69–expressing B cells. B cells for calcium mobilization were gated on the IgG-negative population, which in these subjects consisted mostly of VH1-69+ IgM+ cells. For transcriptome analysis, we extracted RNA from negatively isolated IgM+κ+CD27+ B cells. We maintain that our experimental design represents a reasonable trade-off between cell population purity and absence of unintended BCR stimulation. We disagree with the statement that calcium mobilization in different B-cell subsets was very variable. In fact, in 6 of 8 patients, the CD27+CD21low B-cell fraction had decreased calcium mobilization compared with the CD27+CD21high B-cell fraction. Similarly, in 7 of 8 patients, the CD27−CD21low B-cell fraction had lower calcium mobilization compared with the CD27−CD21high B-cell fraction. We welcome continued research into the induction of attenuation mechanisms in these autoreactive B cells.
  3 in total

1.  The V(H)1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21(low) phenotype.

Authors:  Marcella Visentini; Maria Cagliuso; Valentina Conti; Maurizio Carbonari; Milvia Casato; Massimo Fiorilli
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

2.  Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

Authors:  Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

3.  Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen.

Authors:  G J Nossal; B L Pike
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

  3 in total
  14 in total

1.  Genomic and epigenomic co-evolution in follicular lymphomas.

Authors:  M Loeffler; M Kreuz; A Haake; D Hasenclever; H Trautmann; C Arnold; K Winter; K Koch; W Klapper; R Scholtysik; M Rosolowski; S Hoffmann; O Ammerpohl; M Szczepanowski; D Herrmann; R Küppers; C Pott; R Siebert
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

2.  CREBBP gene mutations are frequently detected in in situ follicular neoplasia.

Authors:  Janine Schmidt; Joan Enric Ramis-Zaldivar; Irina Bonzheim; Julia Steinhilber; Inga Müller; Andrea Haake; Shan Chi Yu; Mark Raffeld; Falko Fend; Itziar Salaverria; Reiner Siebert; Elaine S Jaffe; Leticia Quintanilla-Martinez
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 3.  The heterogeneity of follicular lymphomas: from early development to transformation.

Authors:  Luc Xerri; Stephan Dirnhofer; Leticia Quintanilla-Martinez; Birgitta Sander; John K C Chan; Elias Campo; Steven H Swerdlow; German Ott
Journal:  Virchows Arch       Date:  2015-10-19       Impact factor: 4.064

4.  Colocalization of BCL2-positive and -negative follicular lymphoma.

Authors:  C Laurent; P Brousset
Journal:  Leukemia       Date:  2014-01-27       Impact factor: 11.528

5.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

Review 6.  Nature and importance of follicular lymphoma precursors.

Authors:  Emilie Mamessier; Florence Broussais-Guillaumot; Bruno Chetaille; Reda Bouabdallah; Luc Xerri; Elaine S Jaffe; Bertrand Nadel
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

7.  Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma.

Authors:  J Schmidt; I Salaverria; A Haake; I Bonzheim; P Adam; S Montes-Moreno; M A Piris; F Fend; R Siebert; L Quintanilla-Martinez
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

8.  Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites.

Authors:  Emilie Mamessier; Charlotte Drevet; Florence Broussais-Guillaumot; Marie-Laure Mollichella; Sylvain Garciaz; Sandrine Roulland; Maxime Benchetrit; Bertrand Nadel; Luc Xerri
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

Review 9.  [In situ lymphoma and other early stage malignant non-Hodgkin lymphomas].

Authors:  L Quintanilla-Martínez; P Adam; F Fend
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

10.  Early lesions of follicular lymphoma: a genetic perspective.

Authors:  Emilie Mamessier; Joo Y Song; Franziska C Eberle; Svetlana Pack; Charlotte Drevet; Bruno Chetaille; Ziedulla Abdullaev; José Adelaïde; Daniel Birnbaum; Max Chaffanet; Stefania Pittaluga; Sandrine Roulland; Andreas Chott; Elaine S Jaffe; Bertrand Nadel
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.